You are here

Merck KGaA

Merck KGaA Diversifies with First Female CEO

Merck KGaA Diversifies with First Female CEO

BioSpace

Female Executives

Flag link:

ESMO: Pfizer, Merck KGaA's Bavencio comes up short against placebo in risky head and neck cancer trial

ESMO: Pfizer, Merck KGaA's Bavencio comes up short against placebo in risky head and neck cancer trial

Fierce Pharma

head and neck cancer

clinical trials

Flag link:

Merck KGaA : to Invest EUR59 Million to Expand Pharmaceutical Manufacturing at US Facility

Merck KGaA : to Invest EUR59 Million to Expand Pharmaceutical Manufacturing at US Facility

Market Screener

drug manufacturing

Flag link:

Big pharma spinouts grow up

Big pharma spinouts grow up

EP Vantage

Flag link:

FDA starts quick review of Merck KGaA’s MET-targeting lung cancer drug

FDA starts quick review of Merck KGaA’s MET-targeting lung cancer drug

Pharmaforum

Flag link:

Merck KGaA picks up another anticancer bispecific from F-star

Merck KGaA picks up another anticancer bispecific from F-star

Fierce Biotech

F-star Therapeutics

immuno-oncology

bispecific antibodies

Flag link:

Merck KGaA's manufacturing group could see billions from COVID-19 work: analyst

Merck KGaA's manufacturing group could see billions from COVID-19 work: analyst

Fierce Pharma

drug manufacturing

Flag link:

Merck KGaA’s ATR cancer drug cleared for further trials after phase 1 trial success

Merck KGaA’s ATR cancer drug cleared for further trials after phase 1 trial success

Pharmaforum

clinical trials

Flag link:

Marketing In another round of Merck vs. Merck, Germany-based Merck KGaA notches a win in the U.K.

Marketing In another round of Merck vs. Merck, Germany-based Merck KGaA notches a win in the U.K.

Fierce Pharma

Flag link:

ASCO: Pfizer, Merck KGaA's Bavencio posts win in rare gynecological cancer

ASCO: Pfizer, Merck KGaA's Bavencio posts win in rare gynecological cancer

Fierce Pharma

gestational trophoblastic tumors

clinical trials

Flag link:

Newron's Merck KGaA-in licensed compound fails Rett Syndrome study, shares wilt

Newron's Merck KGaA-in licensed compound fails Rett Syndrome study, shares wilt

Endpoints

clinical trials

Flag link:

German Merck to spend $110M on new gene therapy facility in California

German Merck to spend $110M on new gene therapy facility in California

BioPharma Dive

drug manufacturing

Flag link:

Merck KGaA amps up in gene therapy with $110M viral vector manufacturing boost

Merck KGaA amps up in gene therapy with $110M viral vector manufacturing boost

Fierce Pharma

drug manufacturing

Flag link:

Pharma giants including Novartis collaborate on COVID-19 therapies

Pharma giants including Novartis collaborate on COVID-19 therapies

Pharmaforum

Boehringer Ingelheim

Gilead Sciences

Flag link:

In two-man race with Novartis, Merck scores first regulatory approval for targeted lung cancer drug

In two-man race with Novartis, Merck scores first regulatory approval for targeted lung cancer drug

Endpoints

non-small cell lung cancer

Flag link:

Merck KGaA donates multiple sclerosis med Rebif to French COVID-19 trial

Merck KGaA donates multiple sclerosis med Rebif to French COVID-19 trial

Fierce Pharma

clinical trials

Flag link:

Bavencio from Merck KGaA, Pfizer encounters yet another trial setback

Bavencio from Merck KGaA, Pfizer encounters yet another trial setback

Endpoints

clinical trials

head and neck cancer

Flag link:

Merck KGaA partners with tech firm AMCM on tablet 3D printing

Merck KGaA partners with tech firm AMCM on tablet 3D printing

Pharmaforum

drug manufacturing

Flag link:

To challenge Ocrevus, German Merck takes on Aubagio

To challenge Ocrevus, German Merck takes on Aubagio

EP Vantage

multiple sclerosis

Flag link:

Merck KGaA selling manufacturing site, allergy drugs to Dermapharm

Merck KGaA selling manufacturing site, allergy drugs to Dermapharm

Fierce Pharma

drug manufacturing

Flag link:

Pages